| Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy T Yamazaki, A Kirchmair, A Sato, A Buqué, M Rybstein, G Petroni, N Bloy, ... Nature Immunology 21 (10), 1160-1171, 2020 | 295 | 2020 |
| Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer E García-Martínez, GL Gil, AC Benito, E González-Billalabeitia, ... Breast cancer research 16 (6), 1-17, 2014 | 290 | 2014 |
| Trial Watch: Toll-like receptor agonists in cancer immunotherapy M Smith, E García-Martínez, MR Pitter, J Fucikova, R Spisek, L Zitvogel, ... Oncoimmunology 7 (12), e1526250, 2018 | 236 | 2018 |
| Barriers to radiation-induced in situ tumor vaccination E Wennerberg, C Lhuillier, C Vanpouille-Box, KA Pilones, ... Frontiers in immunology 8, 229, 2017 | 186 | 2017 |
| Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01) A Lluch, CH Barrios, L Torrecillas, M Ruiz-Borrego, J Bines, J Segalla, ... Journal of Clinical Oncology 38 (3), 203, 2020 | 137 | 2020 |
| Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy MAV Conesa, E Garcia-Martinez, EG Billalabeitia, AC Benito, TG Garcia, ... The Breast 21 (4), 468-474, 2012 | 74 | 2012 |
| Angiogenic role of miR-20a in breast cancer G Luengo-Gil, E Gonzalez-Billalabeitia, SA Perez-Henarejos, ... PloS one 13 (4), e0194638, 2018 | 71 | 2018 |
| SEOM clinical guidelines in gestational trophoblastic disease (2017) A Santaballa, Y García, A Herrero, N Laínez, J Fuentes, A De Juan, ... Clinical and Translational Oncology 20 (1), 38-46, 2018 | 61 | 2018 |
| Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer YG Garcia, A de Juan Ferré, C Mendiola, MP Barretina-Ginesta, ... International Journal of Gynecologic Cancer 29 (6), 2019 | 49 | 2019 |
| Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer … MJ Gil-Gil, M Bellet, S Morales, B Ojeda, L Manso, C Mesia, ... Breast cancer research and treatment 151 (3), 597-606, 2015 | 49 | 2015 |
| Radiotherapy cooperates with IL15 to induce antitumor immune responses KA Pilones, M Charpentier, E Garcia-Martinez, C Daviaud, J Kraynak, ... Cancer immunology research 8 (8), 1054, 2020 | 44 | 2020 |
| Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy E García-Martínez, M Smith, A Buqué, F Aranda, FA Peña, A Ivars, ... Oncoimmunology 7 (6), e1433982, 2018 | 44 | 2018 |
| Delayed recovery and increased severity of paclitaxel-induced peripheral neuropathy in patients with diabetes P de la Morena Barrio, MÁV Conesa, E González-Billalabeitia, E Urrego, ... Journal of the National Comprehensive Cancer Network 13 (4), 417-423, 2015 | 42 | 2015 |
| Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables A Ivars Rubio, JC Yufera, P de la Morena, A Fernández Sánchez, ... Scientific reports 9 (1), 16979, 2019 | 37 | 2019 |
| Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy G Luengo-Gil, E García-Martínez, A Chaves-Benito, P Conesa-Zamora, ... Cellular Oncology 42 (5), 627-644, 2019 | 36 | 2019 |
| Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial F Trillsch, S Mahner, F Hilpert, L Davies, E García-Martínez, G Kristensen, ... Annals of Oncology 27 (9), 1733-1739, 2016 | 36 | 2016 |
| Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis G Luengo-Gil, E González-Billalabeitia, A Chaves-Benito, ... Breast cancer research and treatment 151, 577-587, 2015 | 34 | 2015 |
| SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) M Majem, E García-Martínez, M Martinez, E Muñoz-Couselo, ... Clinical and Translational Oncology 22 (2), 213-222, 2020 | 31 | 2020 |
| Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents J Fucikova, L Palova-Jelinkova, V Klapp, P Holicek, T Lanickova, ... Trends in Cancer 8 (5), 426-444, 2022 | 27 | 2022 |
| Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)(GEICO 1205/NOVA TRIAL). Y Garcia Garcia, A De Juan, C Mendiola, MP Barretina-Ginesta, A Prat, ... Journal of Clinical Oncology 35 (15_suppl), 5508-5508, 2017 | 22 | 2017 |
